Showing posts with label HDAC inhibitors. Show all posts
Showing posts with label HDAC inhibitors. Show all posts
Tuesday, April 24, 2012
Journal of Ovarian Research: Thailandepsins are new small molecule class I HDAC inhibitors with potentcytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
Thailandepsins are new small molecule class I HDAC inhibitors with potentcytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
Abstract
Background
New treatment strategies are emerging to target DNA damage response pathways in ovarian cancer. Our group has previously shown that the class I biased HDAC inhibitor romidepsin (FK228) induces DNA damage response and has potent cytotoxic effects in ovarian cancer cells. Here, we investigated newly discovered HDAC inhibitors, thailandepsin A (TDP-A) and thailandepsin B (TDP-B), to determine the effects on cell viability, apoptosis and DNA damage response in ovarian cancer cells......
Thursday, February 18, 2010
HDAC Inhibitors in Cancer Care - Cancer Network
"What is more promising about this study was the utility in all of the cancers studied (ovarian, cervical, breast, testicular, and lung), demonstrating that combining HDAC inhibitors with other therapies may be clinically useful in multiple types of malignancies."
Subscribe to:
Posts
(
Atom
)
